New hope for prostate cancer: drug combo before surgery shows promise

NCT ID NCT06627530

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a combination of two hormone therapies (leuprorelin and darolutamide) for 24 weeks before prostate removal surgery can reduce or eliminate cancer more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate cancer. The main goal is to see if the combination leads to less cancer remaining in the surgical specimen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, São Paulo, 01323001, Brazil

  • Hospital Ophir Loyola

    Belém, Pará, 66063-240, Brazil

  • Hospital São Marcos

    Teresina, Piauí, 64001-280, Brazil

  • Hospital Universitário Pedro Ernesto

    Rio de Janeiro, Rio de Janeiro, 20551-030, Brazil

  • Hospital de Clínicas Ijuí

    Ijuí, Rio Grande do Sul, 98700-000, Brazil

  • Santa Casa de Misericórdia de Feira de Santana

    Feira de Santana, Estado de Bahia, 44001-032, Brazil